Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
This study was designed to assess the safety of indacaterol (300 µg and 600 µg (2 x 300 μg
capsules) once daily [od]), compared with salmeterol (50 μg twice a day [b.i.d.]), over 26
weeks, in patients with moderate to severe persistent asthma.